• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TM7SF3 通过控制 TEAD1 的剪接预防 MASH 诱导的肝纤维化。

TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis.

机构信息

Division of Endocrinology & Metabolism, Department of Medicine, University of California San Diego, La Jolla, CA 92093, USA.

Department of Psychiatry, University of California San Diego, La Jolla, CA 92093, USA.

出版信息

Cell Metab. 2024 May 7;36(5):1030-1043.e7. doi: 10.1016/j.cmet.2024.04.003. Epub 2024 Apr 25.

DOI:10.1016/j.cmet.2024.04.003
PMID:38670107
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11113091/
Abstract

The mechanisms of hepatic stellate cell (HSC) activation and the development of liver fibrosis are not fully understood. Here, we show that deletion of a nuclear seven transmembrane protein, TM7SF3, accelerates HSC activation in liver organoids, primary human HSCs, and in vivo in metabolic-dysfunction-associated steatohepatitis (MASH) mice, leading to activation of the fibrogenic program and HSC proliferation. Thus, TM7SF3 knockdown promotes alternative splicing of the Hippo pathway transcription factor, TEAD1, by inhibiting the splicing factor heterogeneous nuclear ribonucleoprotein U (hnRNPU). This results in the exclusion of the inhibitory exon 5, generating a more active form of TEAD1 and triggering HSC activation. Furthermore, inhibiting TEAD1 alternative splicing with a specific antisense oligomer (ASO) deactivates HSCs in vitro and reduces MASH diet-induced liver fibrosis. In conclusion, by inhibiting TEAD1 alternative splicing, TM7SF3 plays a pivotal role in mitigating HSC activation and the progression of MASH-related fibrosis.

摘要

肝星状细胞 (HSC) 激活和肝纤维化发展的机制尚未完全阐明。在这里,我们表明,一种核七跨膜蛋白 TM7SF3 的缺失会加速肝脏类器官、原代人 HSCs 以及代谢功能障碍相关脂肪性肝炎 (MASH) 小鼠体内的 HSC 激活,导致纤维生成程序和 HSC 增殖的激活。因此,TM7SF3 的敲低通过抑制剪接因子异质核核糖核蛋白 U (hnRNPU) 来促进 Hippo 通路转录因子 TEAD1 的选择性剪接。这导致抑制性外显子 5 的排除,产生更活跃的 TEAD1 形式,并触发 HSC 激活。此外,用特异性反义寡核苷酸 (ASO) 抑制 TEAD1 的选择性剪接可在体外失活 HSCs,并减少 MASH 饮食诱导的肝纤维化。总之,通过抑制 TEAD1 的选择性剪接,TM7SF3 在减轻 HSC 激活和 MASH 相关纤维化进展方面发挥着关键作用。

相似文献

1
TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis.TM7SF3 通过控制 TEAD1 的剪接预防 MASH 诱导的肝纤维化。
Cell Metab. 2024 May 7;36(5):1030-1043.e7. doi: 10.1016/j.cmet.2024.04.003. Epub 2024 Apr 25.
2
Multi-modal analysis of human hepatic stellate cells identifies novel therapeutic targets for metabolic dysfunction-associated steatotic liver disease.人肝星状细胞的多模态分析确定了代谢功能障碍相关脂肪性肝病的新治疗靶点。
J Hepatol. 2025 May;82(5):882-897. doi: 10.1016/j.jhep.2024.10.044. Epub 2024 Nov 8.
3
Phenotypes and ontogeny of senescent hepatic stellate cells in metabolic dysfunction-associated steatohepatitis.代谢相关脂肪性肝炎中衰老肝星状细胞的表型和个体发生。
J Hepatol. 2024 Aug;81(2):207-217. doi: 10.1016/j.jhep.2024.03.014. Epub 2024 Mar 18.
4
Single cell-resolved study of advanced murine MASH reveals a homeostatic pericyte signaling module.晚期小鼠MASH的单细胞解析研究揭示了一种稳态周细胞信号模块。
J Hepatol. 2024 Mar;80(3):467-481. doi: 10.1016/j.jhep.2023.11.001. Epub 2023 Nov 14.
5
OPN-Mediated Crosstalk Between Hepatocyte E4BP4 and Hepatic Stellate Cells Promotes MASH-Associated Liver Fibrosis.骨桥蛋白介导的肝细胞E4BP4与肝星状细胞之间的串扰促进与MASH相关的肝纤维化。
Adv Sci (Weinh). 2024 Dec;11(47):e2405678. doi: 10.1002/advs.202405678. Epub 2024 Oct 29.
6
Coordinated signaling of activating transcription factor 6α and inositol-requiring enzyme 1α regulates hepatic stellate cell-mediated fibrogenesis in mice.激活转录因子 6α 和肌醇需求酶 1α 的协调信号转导调控小鼠肝星状细胞介导的肝纤维化。
Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G864-G879. doi: 10.1152/ajpgi.00453.2020. Epub 2021 Mar 17.
7
A long-acting FGF21 attenuates metabolic dysfunction-associated steatohepatitis-related fibrosis by modulating NR4A1-mediated Ly6C phenotypic switch in macrophages.长效 FGF21 通过调节巨噬细胞中 NR4A1 介导的 Ly6C 表型转换来减轻代谢功能障碍相关脂肪性肝炎相关纤维化。
Br J Pharmacol. 2024 Aug;181(16):2923-2946. doi: 10.1111/bph.16378. Epub 2024 Apr 28.
8
AAV8-mediated silencing of Atad3 prevents the progression from simple steatosis to MASH in mice by reduced IL6 secretion.腺相关病毒8型介导的Atad3基因沉默通过减少白细胞介素6分泌来阻止小鼠从单纯性脂肪变性发展为非酒精性脂肪性肝炎。
Biochim Biophys Acta Mol Basis Dis. 2025 Jun;1871(5):167792. doi: 10.1016/j.bbadis.2025.167792. Epub 2025 Mar 12.
9
Neutrophil extracellular traps activate hepatic stellate cells and monocytes via NLRP3 sensing in alcohol-induced acceleration of MASH fibrosis.中性粒细胞胞外诱捕网通过 NLRP3 感应激活肝星状细胞和单核细胞,加速酒精诱导的 MASH 纤维化。
Gut. 2024 Oct 7;73(11):1854-1869. doi: 10.1136/gutjnl-2023-331447.
10
Naringenin ameliorates MASH fibrosis via regulating TAK1/MAPK/FoxO3a-mediated apoptosis in the activated hepatic stellate cells.柚皮苷通过调节 TAK1/MAPK/FoxO3a 介导的活化肝星状细胞凋亡改善 MASH 纤维化。
Biochem Biophys Res Commun. 2024 Nov 19;734:150732. doi: 10.1016/j.bbrc.2024.150732. Epub 2024 Sep 21.

引用本文的文献

1
Research and application of medicines for treating liver fibrosis: current status and prospects.治疗肝纤维化药物的研究与应用:现状与展望
Front Pharmacol. 2025 Jul 9;16:1582258. doi: 10.3389/fphar.2025.1582258. eCollection 2025.
2
SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.SRSF7通过调节肺成纤维细胞中PKM的可变剪接促进肺纤维化。
Acta Pharm Sin B. 2025 Jun;15(6):3041-3058. doi: 10.1016/j.apsb.2025.04.017. Epub 2025 Apr 22.
3
Alternative splicing: hallmark and therapeutic opportunity in metabolic liver disease.

本文引用的文献

1
Dysregulation of RNA splicing in early non-alcoholic fatty liver disease through hepatocellular carcinoma.早期非酒精性脂肪性肝病中通过肝癌导致的 RNA 剪接失调。
Sci Rep. 2024 Jan 30;14(1):2500. doi: 10.1038/s41598-024-52237-7.
2
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.从非酒精性脂肪性肝炎、代谢功能障碍相关脂肪性肝病到脂肪性肝病:命名更新及其对临床试验的影响
Clin Mol Hepatol. 2023 Oct;29(4):969-972. doi: 10.3350/cmh.2023.0359. Epub 2023 Sep 18.
3
The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment.
可变剪接:代谢性肝病的标志与治疗契机
Gastroenterol Rep (Oxf). 2025 May 26;13:goaf044. doi: 10.1093/gastro/goaf044. eCollection 2025.
4
Single cell multiomics reveals drivers of metabolic dysfunction-associated steatohepatitis.单细胞多组学揭示代谢功能障碍相关脂肪性肝炎的驱动因素。
medRxiv. 2025 May 11:2025.05.09.25327043. doi: 10.1101/2025.05.09.25327043.
5
Regulation of Hepatic Stellate Cell Phenotypes in Metabolic Dysfunction-Associated Steatohepatitis.代谢功能障碍相关脂肪性肝炎中肝星状细胞表型的调控
Gastroenterology. 2025 Mar 20. doi: 10.1053/j.gastro.2025.03.010.
6
Expansion of Splice-Switching Therapy with Antisense Oligonucleotides.反义寡核苷酸介导的剪接转换疗法的扩展
Int J Mol Sci. 2025 Mar 4;26(5):2270. doi: 10.3390/ijms26052270.
7
Current Treatment Regimens and Promising Molecular Therapies for Chronic Hepatobiliary Diseases.慢性肝胆疾病的当前治疗方案及有前景的分子疗法
Biomolecules. 2025 Jan 14;15(1):121. doi: 10.3390/biom15010121.
河马通路效应因子YAP/TAZ-TEAD癌蛋白作为肿瘤微环境中新兴的治疗靶点。
Cancers (Basel). 2023 Jul 2;15(13):3468. doi: 10.3390/cancers15133468.
4
TEAD1 regulates cell proliferation through a pocket-independent transcription repression mechanism.TEAD1 通过一种不依赖于口袋的转录抑制机制来调节细胞增殖。
Nucleic Acids Res. 2022 Dec 9;50(22):12723-12738. doi: 10.1093/nar/gkac1063.
5
A seven-transmembrane protein-TM7SF3, resides in nuclear speckles and regulates alternative splicing.一种七跨膜蛋白——TM7SF3,定位于核斑点并调节可变剪接。
iScience. 2022 Oct 4;25(11):105270. doi: 10.1016/j.isci.2022.105270. eCollection 2022 Nov 18.
6
MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH.miR-690 治疗可减少 NASH 中的纤维化和脂肪变性,并恢复特定的库普弗细胞功能。
Cell Metab. 2022 Jul 5;34(7):978-990.e4. doi: 10.1016/j.cmet.2022.05.008. Epub 2022 Jun 13.
7
Initiation of hepatic stellate cell activation extends into chronic liver disease.肝星状细胞的激活始于慢性肝病。
Cell Death Dis. 2021 Nov 27;12(12):1110. doi: 10.1038/s41419-021-04377-1.
8
RNA splicing programs define tissue compartments and cell types at single-cell resolution.RNA 剪接程序以单细胞分辨率定义组织隔室和细胞类型。
Elife. 2021 Sep 13;10:e70692. doi: 10.7554/eLife.70692.
9
Liver Organoids: Recent Developments, Limitations and Potential.肝脏类器官:最新进展、局限性与潜力
Front Med (Lausanne). 2021 May 5;8:574047. doi: 10.3389/fmed.2021.574047. eCollection 2021.
10
Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.源自 NASH 患者不可逆损伤肝脏的类器官的功能特征。
Hepatology. 2021 Oct;74(4):1825-1844. doi: 10.1002/hep.31857. Epub 2021 Aug 25.